ADReCS

Pharmaceutical Information

Drug Name	Azacitidine
Drug ID	BADD_D00194
Description	A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage	For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status	approved; investigational
ATC Code	L01BC07
DrugBank ID	DB00928
KEGG ID	D03021
MeSH ID	D001374
PubChem ID	9444
TTD Drug ID	D09FAZ
NDC Product Code	0781-9253; 14096-121; 81955-0012; 16729-306; 55150-393; 63323-771; 68001-527; 69097-368; 69097-805; 71288-153; 72485-201; 65129-1222; 68554-0104; 72606-558; 53183-4011; 43598-678; 59572-102; 51916-350; 83137-0006; 16714-927; 43817-906; 59572-730; 68001-504; 71288-115; 63660-0010; 0781-3253; 42385-312; 66529-0013; 54893-0029; 82920-015; 68001-313; 42385-719; 43598-305; 16714-578; 51991-797; 64679-096; 70121-1237; 63592-1800; 0143-9606; 43598-143; 43598-465; 59572-740
UNII	M801H13NRU
Synonyms	Azacitidine \| 5-Azacytidine \| 5 Azacytidine \| Azacytidine \| Vidaza \| NSC-102816 \| NSC 102816 \| NSC102816

Chemical Information

Molecular Formula	C8H12N4O5
CAS Registry Number	320-67-2
SMILES	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hypoxia	22.02.02.003	0.001455%
Ileus	07.13.01.001	0.000280%
Immune system disorder	10.02.01.001	0.000280%		-
Infection	11.01.08.002	-	-	-
Inguinal hernia	07.16.02.001	0.000280%		-
Injection site bruising	08.02.03.042; 12.07.03.042; 23.03.11.015; 24.07.06.017	0.000168%		-
Injection site dermatitis	08.02.03.041; 12.07.03.041; 23.03.04.033	-	-	-
Injection site erythema	08.02.03.001; 12.07.03.001; 23.03.06.015	0.000839%		-
Injection site granuloma	08.02.03.003; 12.07.03.003; 23.03.15.003	-	-	-
Injection site haematoma	08.02.03.004; 12.07.03.004; 24.07.01.009	0.000246%		-
Injection site haemorrhage	08.02.03.005; 12.07.03.005; 24.07.01.010	0.000280%		-
Injection site induration	08.02.03.007; 12.07.03.007	0.000112%		-
Injection site infection	08.02.03.019; 11.01.08.005; 12.07.03.008	-	-	-
Injection site inflammation	08.02.03.008; 12.07.03.009	0.000168%		-
Injection site irritation	08.02.03.027; 12.07.03.027	0.000168%		-
Injection site mass	08.02.03.009; 12.07.03.010	0.000302%		-
Injection site necrosis	08.02.03.020; 12.07.03.020	0.000168%		-
Injection site pain	08.02.03.010; 12.07.03.011	0.000940%		-
Injection site pruritus	08.02.03.013; 12.07.03.014; 23.03.12.007	-	-	-
Injection site rash	08.02.03.032; 12.07.03.032; 23.03.13.010	0.000112%		-
Injection site reaction	08.02.03.014; 12.07.03.015	0.003313%
Injection site vesicles	08.02.03.051; 12.07.03.051; 23.03.01.024	0.000112%		-
Insomnia	17.15.03.002; 19.02.01.002	-	-
Interstitial lung disease	10.02.01.033; 22.01.02.003	0.002574%		-
Intestinal obstruction	07.13.01.002	0.000504%		-
Intestinal ulcer	07.04.06.003	0.000112%		-
Large intestine perforation	07.04.06.005; 12.02.03.005	0.000224%
Laryngeal pain	22.12.03.010	0.000168%
Left ventricular failure	02.05.02.001	0.000112%		-
Lethargy	08.01.01.008; 17.02.04.003; 19.04.04.004	-	-

The 7th Page First Pre 7 8 9 10 11 Next Last Total 19 Pages